• Trulieve Cannabis Merges With Harvest Health

    The medical marijuana market just got its biggest merger. Trulieve Cannabis Corp. (OTC: TCNNF), a vertically integrated “seed-to-sale” company, announced last week the acquisition of Harvest Health & Recreation Inc. for $2.1 billion. Harvest Health is a vertically integrated medical cannabis company and multi-state... Read More »
  • Amedisys Acquires VNA Home Health Business

    The home health giant Amedisys, Inc. (NASDAQ: AMED) announced last week it was acquiring the home health business of Visiting Nurse Association in Omaha, Nebraska. The business has 400 providers serving Omaha, Council Bluffs and surrounding communities.  The financial terms of the deal were not disclosed, although the companies said they expect... Read More »
  • Community Psychiatry Management Expands Its Network

    The San Francisco-based behavioral healthcare company Community Psychiatry Management, LLC is expanding its footprint. The company last week announced the acquisition of MindPath Care Centers, which provides medication management and individual therapy both in-office and via telehealth, addiction recovery services, group therapy sessions and... Read More »
  • Health Care M&A Deals, May 14, 2021

    The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our HealthCareMandA.com Deal Database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry. The largest deal... Read More »
  • Science 37 Goes Public in SPAC Deal

    Another week, another SPAC deal. This time, Science 37, Inc. is merging with LifeSci Acquisition II Corp. (NASDAQ: LSAQ), a special purpose acquisition company (SPAC) targeting the biopharma, medical technology, digital health and healthcare services sectors. The transaction values Science 37 at a total enterprise value of $1.05 billion and a... Read More »
Takeda Takes Aim at Shire

Takeda Takes Aim at Shire

Big Pharma deals are making a comeback. Or so it seems from the speculation around Shire plc (NASDAQ: SHPG). Japanese drug maker Takeda Pharmaceutical Co. (OTCQB: TKPYY) has been buzzing around the UK-based Shire for nearly a month, making bid after bid. It seemed to begin on April 16, when Shire sold its oncology business to the French drug maker Servier, for $2.4 billion in cash. In 2017, the 0ncology business generated revenues of $262 million. The total consideration represents a revenue multiple of 9.2x 2017 revenues. The acquisition gives Servier a direct commercial presence in the United States and boosts its presence in cancer. Servier’s products will be commercialized in the... Read More »